The Waltham, Mass.-based company priced its public offering at $15.00 per share, granting underwriters an option to buy up to 900,000 additional shares. The exercise of this option brought the proceeds of its IPO up from $90 million to $103.5 million, Kala reported.
In May, Kala touted data from a Phase III trial of its nanoparticle formulation of loteprednol etabonate as a treatment for inflammation and pain in cataract surgery patients. The KPI-121 1% suspension met both primary efficacy endpoints and secondary endpoints and was well tolerated by the trial’s participants.
The company’s KPI-121 uses Kala’s mucus-penetrating particle technology to deliver drugs to tissues in the eye. In preclinical studies, MPP tech increased loteprednol etabonate delivery to ocular tissues 4-fold, according to the company.
The Phase III trial enrolled 520 patients with anterior ocular inflammation after cataract surgery and randomized them to receive the KPI-121 1% or a placebo twice a day for 2 weeks. The primary efficacy endpoints were the proportion of patients with complete resolution of anterior chamber cells at day 8 and the proportion of participants with Grade 0 pain in the study eye after 8 days.
The study met both primary endpoints and achieved its secondary endpoints, including compete resolution of anterior chamber flare at day 4 and complete resolution of pain after 4 days.
KALA shares were trading at $19.14 apiece in morning activity today, down -0.3%.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.